10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
出版年份 2013 全文链接
标题
10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
作者
关键词
-
出版物
CLINICAL INFECTIOUS DISEASES
Volume 56, Issue 12, Pages 1685-1694
出版商
Oxford University Press (OUP)
发表日期
2013-04-19
DOI
10.1093/cid/cit152
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- β-Lactam antimicrobials: what have you done for me lately?
- (2012) George H. Talbot Annals of the New York Academy of Sciences
- Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette ChromosomemecTypes
- (2012) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria
- (2012) Elizabeth B. Hirsch et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
- (2012) Premavathy Levasseur et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic
- (2012) Trudy H. Grossman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Progress on Developing Endpoints for Registrational Clinical Trials of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections: Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health
- (2012) George H. Talbot et al. CLINICAL INFECTIOUS DISEASES
- White Paper: Recommendations on the Conduct of Superiority and Organism-Specific Clinical Trials of Antibacterial Agents for the Treatment of Infections Caused by Drug-Resistant Bacterial Pathogens
- (2012) CLINICAL INFECTIOUS DISEASES
- Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)
- (2012) Neil Fishman et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii
- (2012) P. G. Higgins et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The Perpetual Challenge of Infectious Diseases
- (2012) Anthony S. Fauci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activity of ACHN-490 Tested Alone and in Combination with Other Agents against Pseudomonas aeruginosa
- (2011) Glenn A. Pankuch et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Ceftazidime-NXL104 against 396 Strains of β-Lactamase-Producing Anaerobes
- (2011) Diane M. Citron et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VivoEfficacy of a Human-Simulated Regimen of Ceftaroline Combined with NXL104 against Extended-Spectrum-β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Enterobacteriaceae
- (2011) Dora E. Wiskirchen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)
- (2011) A. Walkty et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases
- (2011) P. R. S. Lagacé-Wiens et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- New antimicrobial agents on the horizon
- (2011) Karen Bush et al. BIOCHEMICAL PHARMACOLOGY
- Can We Really Use ss-Lactam/ss-Lactam Inhibitor Combinations for the Treatment of Infections Caused by Extended-Spectrum ss-Lactamase-Producing Bacteria?
- (2011) F. Perez et al. CLINICAL INFECTIOUS DISEASES
- Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
- (2011) CLINICAL INFECTIOUS DISEASES
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
- In vitro activity of BAL30072 against Burkholderia pseudomallei
- (2011) Takehiko Mima et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antibiotics in the clinical pipeline in 2011
- (2011) Mark S Butler et al. JOURNAL OF ANTIBIOTICS
- In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii
- (2011) T. A. Russo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae
- (2010) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-ProducingKlebsiella pneumoniae
- (2010) Andrea Endimiani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli
- (2010) M. G. P. Page et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020
- (2010) CLINICAL INFECTIOUS DISEASES
- Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia
- (2010) Brad Spellberg et al. CLINICAL INFECTIOUS DISEASES
- The future of the β-lactams
- (2010) Leticia I Llarrull et al. CURRENT OPINION IN MICROBIOLOGY
- Combating evolution with intelligent design: the neoglycoside ACHN-490
- (2010) Eliana S Armstrong et al. CURRENT OPINION IN MICROBIOLOGY
- New β-lactam antibiotics and β-lactamase inhibitors
- (2010) Karen Bush et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Multidrug Resistance among Gram-Negative Pathogens That Caused Healthcare-Associated Infections Reported to the National Healthcare Safety Network, 2006–2008
- (2010) Alexander J. Kallen et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
- (2010) S. Mushtaq et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Updated Functional Classification of -Lactamases
- (2009) K. Bush et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters
- (2009) S. Mushtaq et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge
- (2009) Cesar A. Arias et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
- (2008) Helen W. Boucher et al. CLINICAL INFECTIOUS DISEASES
- Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
- (2008) Louis B. Rice JOURNAL OF INFECTIOUS DISEASES
- The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America
- (2007) B. Spellberg et al. CLINICAL INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started